Ligand Pays $23M for Royalties on Santen’s Myopia Drug Ryjunea…

Event summary

Ligand acquires tiered royalty interest in Ryjunea, a pediatric myopia treatment, for $23M upfront.
Ryjunea is the first and only approved pharmacological treatment for myopia in the EU and UK.
Ligand will receive low-double-digit to high-teens royalties on Ryjunea net sales in EMEA.
Santen estimates 14 million pediatric myopia patients in Europe in 2025, with projections of 1 in 3 affected by 2050.

The big picture

Ligand’s acquisition of Ryjunea royalties aligns with its strategy of diversifying its portfolio with high-growth, late-stage assets. The deal underscores the rising demand for pediatric myopia treatments, a condition projected to affect a third of European children by 2050. Santen’s strong ophthalmology presence in the region positions Ryjunea for long-term commercial success, though competition from compounded atropine and optical treatments remains a wildcard.

What we're watching

Commercial Execution: Whether Santen can effectively commercialize Ryjunea in a competitive myopia treatment landscape.
Market Growth: The pace at which pediatric myopia prevalence expands in Europe, influencing Ryjunea’s revenue potential.
Royalty Performance: How Ligand’s tiered royalty structure will translate into actual returns given Ryjunea’s market adoption.